Abstract
The prevalence of Hepatitis C viral infection in Egypt is the highest rate in the world. It is a major public health problem in Egypt. The objective of this study was to detect the clearance of HCV-RNA in Egyptian patients who were recommended for combination therapy of pyglated interferon α 2a and ribavirin (PEG-interferon/Ribavirin). Ninety-five positive HCV-IgG cases were tested for HCV-RNA at baseline and at weeks 4, 12, 24, 48 and 72 of treatment with PEG-interferon α 2a/Ribavirin. The correlations between the viral parameters during and after treatment were evaluated. Patients recommended receiving PEG-interferon 2a/ribavirin combination therapy showed high response rate determined as 71.9% achieved Sustained Virological Response (SVR) from total patients, and 71.4% from patients who received 48 weeks therapy. In general, the employment of TMA provided us the accuracy of results with confidence in our work. There was a significant relation (p < 0.001) between results of Transcription mediated amplification (TMA) and response to therapy that indicate to positive correlation. The development of sensitive accurate assays for HCV-RNA detection and quantification is necessary to improve not only the assessment of the response to antiviral therapy but also our understanding of the mechanism underlying antiviral resistance.
Highlights
The best and standard approach to monitoring for treatment affectivity consists of continual measuring of quantitative HV-RNA levels
The objective of this study was to detect the clearance of HCV-RNA in Egyptian patients who were recommended for combination therapy of pyglated interferon α 2a and ribavirin (PEG-interferon/Ribavirin)
This study aimed to investigate the clearance of HCVRNA in Egyptian patients who were recommended for combination therapy of pyglated interferon α 2a and ribavirin (PEG-interferon/Ribavirin)
Summary
The best and standard approach to monitoring for treatment affectivity consists of continual measuring of quantitative HV-RNA levels. Transcription mediated amplification (TMA) is the most sensitive qualitative HCV RNA assay, of detection limit that start from 5 IU/ml and sensitivity more than 98% to confirm viremia and to detect clearance of viremia during and after the completion of the treatment [5]. The third generation assay (bDNA 3.0) has a high dynamic range of lower detection limit of 615 IU/ml and an upper range of 7.7 million IU/ml It is highly reproducible and the specificity range from 96% to 98% [6]. The previously mentioned nucleic acid tests (NATs) are very important combined with each other’s to monitor clearance of HCV-RNA in therapeutic treated patients with a global TMA technology Confirmation. This study aimed to investigate the clearance of HCVRNA in Egyptian patients who were recommended for combination therapy of pyglated interferon α 2a and ribavirin (PEG-interferon/Ribavirin). This enables us to evaluate the different responses to the combination therapy of PEG-interferon/Ribavirin as a good used regimen in treatment of chronic HCV in Egyptian patients
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
